REG - ReNeuron Group plc - Posting of AR & Accounts & Notice of AGM

ReNeuronAnnouncement

15/08/2022 15:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220815:nRSO0688Wa&default-theme=true

RNS Number : 0688W  ReNeuron Group plc  15 August 2022

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Posting of Annual Report & Accounts

& Notice of AGM

 

ReNeuron  Group  plc  (AIM:  RENE), a UK-based  stem  cell  leader in
stem cell derived exosome technologies, announces that its Annual Report and
Accounts for the year ended 31 March 2022 and the Notice of the 2022 Annual
General Meeting ("AGM") have today been sent to shareholders and are also
available on the Company's website at www.reneuron.com
(http://www.reneuron.com/) .

 

ReNeuron's AGM will be held at 09.30am on Friday 9 September 2022 at the
offices of Covington and Burling LLP, Level 54, 22 Bishopsgate, London, EC2N
4BQ

 

At the time of publication of the notice of AGM, the Government has lifted
most legal restrictions relating to public gatherings that had previously been
in place due to the ongoing COVID-19 Pandemic. In line with this, the Board
welcomes the opportunity to invite shareholders to attend the AGM in person
Should this situation change, shareholders will be notified though our website
www.reneuron.com (http://www.reneuron.com/) and, where appropriate by RNS.
Attendees will need to pre-register, please refer to the Notice of AGM or to
your proxy card for information on how to do so.

 

Shareholders are encouraged to send any questions for the Chairman to
info@reneuron.com (mailto:info@reneuron.com) at least 48 hours prior to the
meeting. Where appropriate, such questions and answers will be collated and
later published, together with full voting details, in the Investor Centre of
the Company's website at www.reneuron.com (http://www.reneuron.com) .

 

 

ENDS

 

 

Contacts:

 

 ReNeuron                                          www.reneuron.com/investors (http://www.reneuron.com/investors)
 Iain Ross, Chairman                               Via Walbrook PR
 Catherine Isted, Chief Financial Officer

 Liberum Capital Limited (NOMAD and Joint Broker)  +44 (0)20 3110 2000

 Phil Walker (Investment Banking)

 Richard Lindley (Investment Banking)

 Ben Cryer (Investment Banking)

 Allenby Capital Limited (Joint Broker)            +44 (0)20 3328 5656
 James Reeve/George Payne (Corporate Finance)
 Stefano Aquilino (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)          +44 (0)20 7933 8780 or reneuron@walbrookpr.com
                                                   (mailto:reneuron@walbrookpr.com)
 Alice Woodings                                    +44 (0)7407 804 654

 

 

About ReNeuron

ReNeuron is a UK based leader in proprietary stem cell derived exosome
technologies, harnessing its unique stem cell technologies to develop 'off the
shelf' treatments for diseases with significant unmet needs.

 

ReNeuron's stem cell derived proprietary exosome technology platform offers a
delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins,
small molecules and genes. The Group has a growing number of partner
collaborations with Global Pharma, Biotech and academic partners in this
fast-expanding area of scientific and commercial interest. ReNeuron also has
the ability, through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform, to make allogeneic tissue cells of choice and has the
potential to produce exosomes with tissue specific targeting ability.

 

The Group has out-licenced its CTX Programme for stroke disability and hRPC
programme in retinitis pigmentosa to Fosun in China and is looking to
out-license both of these programmes in other territories.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAGPUMGRUPPGCA